Impact of the COVID-19 Pandemic on the Therapeutic Continuity among Outpatients with Chronic Cardiovascular Therapies.
COVID-19 pandemic
adherence
cardiovascular diseases
chronic treatments
prescriptions
Journal
International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455
Informations de publication
Date de publication:
24 09 2022
24 09 2022
Historique:
received:
25
08
2022
revised:
20
09
2022
accepted:
21
09
2022
entrez:
14
10
2022
pubmed:
15
10
2022
medline:
18
10
2022
Statut:
epublish
Résumé
The COVID-19 pandemic poses major challenges to healthcare systems. We aimed to investigate the impact of the pandemic on prescription and adherence patterns of chronic cardiovascular therapies (lipid-lowering [LL], oral antidiabetic drugs [AD], and antihypertensives [AH]) using administrative pharmaceutical databases. For each treatment, two cohorts of prevalent cases in 2019 and 2020 were compared. We evaluated the percentage change in dispensed packages and treatment adherence as a proportion of days covered (PDC). For all therapies, an increase was observed during March-April 2020 (LL: +4.52%; AD: +2.72%; AH: +1.09%), with a sharp decrease in May-June 2020 (LL: -8.40%; AD: -12.09%; AH: -10.54%) compared to 2019. The impact of the COVID-19 pandemic on chronic cardiovascular treatments appears negligible on adherence: 533,414 patients showed high adherence to LL (PDC ≥ 80%) in January-February 2020, and 2.29% became poorly adherent (PDC < 20%) in the following four-month period (vs. 1.98% in 2019). A similar increase was also observed for AH (1.25% with poor adherence in 2020 vs. 0.93% in 2019). For AD, the increase was restrained (1.55% with poor adherence in 2020 vs. 1.37% in 2019). The rush to supply drugs at the beginning of lockdown preserved the continuity of chronic cardiovascular therapies.
Identifiants
pubmed: 36231403
pii: ijerph191912101
doi: 10.3390/ijerph191912101
pmc: PMC9566639
pii:
doi:
Substances chimiques
Antihypertensive Agents
0
Hypoglycemic Agents
0
Lipids
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Int J Environ Res Public Health. 2020 Dec 18;17(24):
pubmed: 33352883
Indian J Ophthalmol. 2021 May;69(5):1264-1270
pubmed: 33913874
J Cardiovasc Dev Dis. 2021 Nov 02;8(11):
pubmed: 34821699
Fam Med Community Health. 2021 Aug;9(3):
pubmed: 34344766
Drug Saf. 2019 Mar;42(3):347-363
pubmed: 30269245
Ann Transl Med. 2020 Sep;8(18):1179
pubmed: 33241028
Eur Heart J. 2013 Oct;34(38):2940-8
pubmed: 23907142
Am J Manag Care. 2009 Jul;15(7):457-64
pubmed: 19589013
Epilepsy Behav. 2021 Apr;117:107833
pubmed: 33618316
Connect Health. 2022 Jan 4;1:7-35
pubmed: 35233563
Front Pharmacol. 2021 Jun 07;12:685696
pubmed: 34163364
Eur Geriatr Med. 2020 Jun;11(3):369-381
pubmed: 32297271
PLoS One. 2021 Aug 13;16(8):e0253944
pubmed: 34388166
PLoS One. 2021 Mar 22;16(3):e0248995
pubmed: 33750990
PLoS One. 2021 Apr 1;16(4):e0249453
pubmed: 33793663
Curr Opin Cardiol. 2011 Jul;26(4):279-87
pubmed: 21597368
Health Policy. 2021 Aug;125(8):995-1001
pubmed: 34099317
Lancet Reg Health Eur. 2021 May;4:100099
pubmed: 33875981
Res Social Adm Pharm. 2021 Jan;17(1):2023-2026
pubmed: 32307319
Diabetes Res Clin Pract. 2021 Oct;180:109047
pubmed: 34530061
JACC Case Rep. 2020 Jul 15;2(9):1414-1418
pubmed: 32835287
Adv Exp Med Biol. 2021;1353:91-113
pubmed: 35137370
J Gerontol A Biol Sci Med Sci. 2020 Sep 16;75(9):e119-e120
pubmed: 32222763
J Am Pharm Assoc (2003). 2022 May-Jun;62(3):834-839.e1
pubmed: 34844885
Proc Natl Acad Sci U S A. 2020 May 12;117(19):10484-10491
pubmed: 32327608
Front Public Health. 2021 Feb 03;9:623904
pubmed: 33614587
Front Public Health. 2020 Nov 23;8:583583
pubmed: 33330324
N Engl J Med. 2020 Jun 11;382(24):2368-2371
pubmed: 32302076
JAMA Netw Open. 2020 Nov 2;3(11):e2024984
pubmed: 33151319